Japanese drug manufacturer Takeda Pharmaceutical indicated that the company is attempting to develop a drug based on the blood of patients who recovered from COVID-19.
Gilead Sciences Inc. started two late-stage studies to test the company’s drug in patients with severe and moderate cases of the illness caused by the coronavirus, sending the drug firm’s shares up.
One of the largest concussion studies ever conducted found that a new blood test developed by Abbott was able to detect a protein in the blood that confirmed a concussion, even if the result of a CT scan came back negative.
AstraZeneca made strides toward the company’s goal of adding heart failure to the conditions that can be treated by Farxiga, putting the diabetes drug ahead of a rival medicine from Eli Lilly.
The only liver disease becoming more widespread in the U.S. is one driven by obesity and diabetes – NAFLD – even as other liver disorder types linked to drinking or hepatitis become less common.
Essenlix Corporation announced the development of the world’s smallest, simplest, and lowest-cost blood count device – iMOST-CBC (instant mobile self-test for complete blood count).
If you have received a vaccination, hip replacement or chemotherapy without suffering toxic shock, chances are you have benefited from a vast bloodletting of horseshoe crabs.
A new study found that taking 4,000 international units per day may double the amount of vitamin D in the blood, but it gives most people roughly the same chance of developing blood sugar problems as people who do not take the vitamin.
Early detection of cardiovascular disease is becoming possible due to research from Giovanna Guidoboni, Marjorie Skubic and a team at the University of Missouri.
Johnson & Johnson agreed to pay about $1 billion to resolve the bulk of lawsuits claiming the company sold defective metal-on-metal hip implants that ultimately had to be removed, Bloomberg reported, citing people with knowledge of the matter.
